News - October 30, 2020

JOIN US: Case studies on rare disease therapies development – A laboratory of ideas for European innovation leadership

Pharmaceutical small to mid-sized companies and start-ups constitute a laboratory of innovation and should be nurtured through a forward-looking European incentives ecosystem that encourages the development of cutting-edge technologies.

The upcoming EU health policy initiatives, including the Pharmaceutical Strategy for Europe and the impact assessment following the evaluation of the OMP and Paediatric Regulations, provide a unique opportunity to harness this potential.

On behalf of EUCOPE and SME Connect, we invite you to join us on 20 November from 15:00 to 16:00 (CET) for navigating through two medium sized pharmaceutical companies’ journey and experiences, exploring with European and national policymakers, industry representatives and other stakeholders future ideas and actionable solutions to strengthen European innovation leadership in the healthcare sector.

We will seize the opportunity to share with speakers and audience some ideas and recommendation from the upcoming EUCOPE’s paper ‘’The Orphan Medicines Regulation – the Way Forward’ to be unveiled following this event.

You can register at this link.

See below the agenda for the day:


Dr. Paul Rübig – President SME Connect; Board Member European Institute of Innovation and Technology (EIT); MEP 1996-2019


Maria Da Graça Carvalho, Member of the European Parliament


Fabio D’Atri – Policy Officer, Unit B5 Medicines: policy, authorisation and monitoring, European Commission

Annik K-Laflamme – VP Medical & Scientific Affairs – Global Medical & Scientific Affairs, Sobi

Clémence RossVan Dorp – Former Dutch State Secretary for Health, Welfare and Sport, Ambassador Action Program ‘New chances Topsector Life Sciences & Health’, Dutch Ministry Economic Affairs

Julien Patris – Country Business Lead – Belgium & Luxembourg, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam Pharmaceuticals

Moderated by Dr. Alexander Natz – Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)